Cronobacter

Reckitt/Mead Johnson Nutrition Voluntarily Recalls Select Batches of Nutramigen Hypoallergenic Infant Formula Powder Because of Possible Health Risk

Retrieved on: 
Sunday, December 31, 2023
Retail, Health, Consumer, Fitness & Nutrition, Specialty, Baby, Maternity, Food, Beverage, Infant, Cronobacter, Safety, Reckitt, Bacteria, Parent, World Health Organization

Other testing of the batches in question tested negative for Cronobacter and other bacteria.

Key Points: 
  • Other testing of the batches in question tested negative for Cronobacter and other bacteria.
  • It is for this reason that we have confidence in the safety and quality of every infant formula we make.
  • Consumers who purchased Nutramigen should check the bottom of the can to identify whether the batch number is affected.
  • Please contact us at 866-534-9986 or by email at [email protected] and we will help verify if this product was impacted.

New Campaign from Food Safety Attorney Bill Marler Urges Council to Make Pathogen Cronobacter sazakii Reportable

Retrieved on: 
Tuesday, May 9, 2023
Cronobacter, State, Food, Syndrome, Abbott, Escherichia coli, History, Person, CDC, Death, Report, Dysentery, Council of State and Territorial Epidemiologists, Child, Council, Infant, Infection, Congress, FDA, Meat, Dietary supplement, Vaccine, Poultry farming

SEATTLE, May 9, 2023 /PRNewswire/ -- Bill Marler, a food safety attorney, has launched a campaign with t-shirts stating, "For Babies Sake, Make Cronobacter sazakii Reportable". After reviewing the investigation into the Abbot infant formula outbreak and recall, Marler believes that it could have been prevented if the law required reporting Cronobacter sazakii as an adulterant in food. Currently only two states require reporting of Cronobacter sazakii.  

Key Points: 
  • SEATTLE, May 9, 2023 /PRNewswire/ -- Bill Marler, a food safety attorney, has launched a campaign with t-shirts stating, "For Babies Sake, Make Cronobacter sazakii Reportable".
  • After reviewing the investigation into the Abbot infant formula outbreak and recall, Marler believes that it could have been prevented if the law required reporting Cronobacter sazakii as an adulterant in food.
  • "Make infant formula safe by making Cronobacter sazakii reportable", said Bill Marler.
  • "I hope that these t-shirts will be a reminder of the awesome responsibility that this council has to protect the public," said Marler.

Health Canada provides update on supply of infant formula in Canada

Retrieved on: 
Tuesday, March 21, 2023
Cronobacter, Communication, Pharmacy, Parent, Policy, Canadian Food Inspection Agency, Health, Child, Infant, Health Canada, Parents' Choice Award, Caregiver, Dietary supplement

OTTAWA, ON, March 21, 2023 /CNW/ - Health Canada understands that any disruptions to the supply of infant formula can be distressing for parents and caregivers and shares their concerns.

Key Points: 
  • OTTAWA, ON, March 21, 2023 /CNW/ - Health Canada understands that any disruptions to the supply of infant formula can be distressing for parents and caregivers and shares their concerns.
  • While the total national supply of regular infant formula remains sufficient at this time, we are aware of concerns about finding store-brand or lower-cost infant formulas.
  • Health Canada continues to do everything it can to mitigate the situation to provide families with the infant formula they need.
  • Health Canada estimates that the recalled product represents a very small proportion of the Canadian powdered infant formula market.

ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT

Retrieved on: 
Saturday, March 4, 2023
Class Action Lawsuit, Professional Services, Legal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cronobacter, Food, Abbott Laboratories, Infant, FDA, Death, NYSE, OSHA, Laboratory, KSF

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Abbott Laboratories (NYSE: ABT).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Abbott Laboratories (NYSE: ABT).
  • KSF’s investigation is focusing on whether Abbott’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.
  • KSF has offices in New York, California, Louisiana and New Jersey.

Reckitt Recalls Two Batches of ProSobee 12.9 oz Simply Plant-Based Infant Formula Because of Possible Health Risk

Retrieved on: 
Monday, February 20, 2023
Women, Parenting, Other Retail, Baby, Maternity, Fitness & Nutrition, Supermarket, Food, Beverage, Consumer, Health, Retail, Cronobacter, World Health Organization, Safety, Infant, Parent, Cronobacter sakazakii, Bacteria, Universal Product Code, Multimedia, Infant formula, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dietary supplement, Reckitt

Simply Plant-Based Infant Formula due to a possibility of cross-contamination with Cronobacter sakazakii.

Key Points: 
  • Simply Plant-Based Infant Formula due to a possibility of cross-contamination with Cronobacter sakazakii.
  • No other ProSobee Simply Plant-Based Infant Formula batches or other Reckitt products are impacted.
  • It is for this reason that we have the highest level of confidence in the safety and quality of every infant formula we make.
  • Consumers who purchased ProSobee Simply Plant-Based Infant Formula should check the bottom of the can to identify whether the batch number is affected.

2022 in Press Releases: The Year's Must-Read Stories

Retrieved on: 
Friday, December 30, 2022
Online, Sony, OTC, Related, Travel, Bank, PR Newswire, Hearing aid, Rest, FTX, News, Great Lakes, ProfNet, Kool-Aid, Radio, Housing, Financial health management, Macdonald, Face, HARD, FDA, LensCrafters, Eating, Court TV, Great Lakes region, Cronobacter, MTN, Hibernation, Parler, Subject-matter expert, Bank of America, Weather, Cronobacter sakazakii, Multimedia, Parent, Database, Extreme, Sale, Acquisition, Hospital, Internet, Social media, Ye, LendingClub, Transport, Heart, Capital Dynamics (global asset manager), DeLorean, EBay, Happy Meal, Walmart, Publication, Musk, Emotion, Mental health, Farmer, Legislation, Geography, Publishing, Video game console, Cryptocurrency

NEW YORK, Dec. 30, 2022 /PRNewswire/ -- With more than 300,000 press releases hitting the wire this year, it was difficult to keep up with everything on PR Newswire. As another year at the wire comes to an end, the team is recapping some major stories from 2022 that couldn't be missed.

Key Points: 
  • As another year at the wire comes to an end, the team is recapping some major stories from 2022 that couldn't be missed.
  • Some strayed from the more "traditional" press release format to focus on storytelling and appeal to readers' emotions.
  • Click on the press release headlines to access the full story and accompanying multimedia assets that are available for download.
  • PR Newswire thoroughly researches and vets this community to verify their identity as a member of the press, blogger or influencer.

ABBOTT LABORATORIES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

Retrieved on: 
Saturday, October 29, 2022
Class Action Lawsuit, Professional Services, Legal, Company, Special warfare combatant-craft crewmen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, District court, OSHA, Similac, Food, Cronobacter, Abbott Laboratories, Court, News, LLC, FDA, Lists of schools in England, Infant, Laboratory, NYSE, KSF, Firefighter, Insurance, Medical device

This action is pending in the United States District Court for the Northern District of Illinois.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of Illinois.
  • Abbott and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • The case is Pembroke Pines Firefighters & Police Officers Pension Fund v. Abbott Laboratories, No.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Abbott Investors: Please Contact the Portnoy Law Firm to Recover Your Losses; Last Days to Actively Participate in the Case; October 31, 2022

Retrieved on: 
Thursday, October 27, 2022
Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Safety, OSHA, Risk, Similac, Bacteria, Food, Abbott Laboratories, Complaint, News, GLOBE, Review, FDA, Lists of schools in England, Infant, NYSE, Cronobacter sakazakii, United, Life insurance, Risk management, Pharmaceutical industry, Cronobacter

Abbott investors with over $500,000 in losses on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • Abbott investors with over $500,000 in losses on their investment are encouraged to contact Lesley Portnoy, Esq.
  • Please contact attorney Lesley F. Portnoy ,by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • By early 2022, Abbott was responsible for producing 40 percent of the United States infant formula.

ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

Retrieved on: 
Wednesday, October 26, 2022
Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, District court, OSHA, Similac, Food, Abbott, Cronobacter, Abbott Laboratories, Lawyer, News, GLOBE, LLC, FDA, Lists of schools in England, FREE, Infant, Laboratory, NYSE, Firefighter, Medical device

This action is pending in the United States District Court for the Northern District of Illinois.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of Illinois.
  • Abbott investors should visit us at https://claimsfiler.com/cases/nyse-abt-1/ or call toll-free (844) 367-9658.
  • Abbott and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, October 25, 2022
Company, Similac, Labour government, Laboratory, NYSE, Death, District court, GLOBE, NEW, FDA, Infant, Investment, Securities Exchange Act of 1934, Bacteria, Cronobacter sakazakii, News, Food and Drug Administration, United, The Legal 500, Advertising, Court, Safety, Fine chemical, Online gambling, Medical device, Cronobacter, Abbott Laboratories

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.